ROCKVILLE, Md., May 12 EntreMed, Inc. (Nasdaq: ENMD), today announced that it will issue its first quarter 2010 financial results on Tuesday, May 18, 2010 at 7:00 a.m. EDT.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
The company will host a conference call at 10:00 a.m. EDT on Tuesday, May 18, 2010. EntreMed Executive Chairman, Mr. Michael M. Tarnow, will lead the call and provide an update on the Company's progress and strategy.
To access the live teleconference, please dial 877-801-3560 (U.S. or Canada) or 706-643-6822 (internationally) and reference conference number 73228525 10 minutes prior to the beginning of the call. A digital recording will be available approximately two hours after completion of the conference call and will be accessible for 90 days. To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the Conference ID number 73228525. An audio replay will also be available on the Company's web site at www.entremed.com approximately two hours after the conclusion of the live conference.
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CONTACT: Ginny Dunn Associate Director, Corporate Communications & Investor Relations EntreMed, Inc. 240.864.2643
SOURCE EntreMed, Inc.